{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23442265",
  "DateCompleted": {
    "Year": "2013",
    "Month": "11",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2013",
    "Month": "11",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2013",
        "Month": "02",
        "Day": "26"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1017/S0007114513000391"
    ],
    "Journal": {
      "ISSN": "1475-2662",
      "JournalIssue": {
        "Volume": "110",
        "Issue": "7",
        "PubDate": {
          "Year": "2013",
          "Month": "Oct"
        }
      },
      "Title": "The British journal of nutrition",
      "ISOAbbreviation": "Br J Nutr"
    },
    "ArticleTitle": "Human milk oligosaccharides inhibit rotavirus infectivity in vitro and in acutely infected piglets.",
    "Pagination": {
      "StartPage": "1233",
      "EndPage": "1242",
      "MedlinePgn": "1233-42"
    },
    "Abstract": {
      "AbstractText": [
        "Human milk (HM) is rich in oligosaccharides (HMO) that exert prebiotic and anti-infective activities. HM feeding reduces the incidence of rotavirus (RV) infection in infants. Herein, the anti-RV activity of oligosaccharides was tested in an established in vitro system for assessing cellular binding and viral infectivity/replication, and also tested in a newly developed, acute RV infection, in situ piglet model. For the in vitro work, crude HMO isolated from pooled HM, neutral HMO (lacto-N-neotetraose, LNnT; 2'-fucosyllactose) and acidic HMO (aHMO, '-sialyllactose, 3'-SL; -sialyllactose, -SL) were tested against the porcine OSU strain and human RV Wa strain. The RV Wa strain was not inhibited by any oligosaccharides. However, the RV OSU strain infectivity was dose-dependently inhibited by sialic acid (SA)-containing HMO. 3'-SL and 6'-SL concordantly inhibited (125)I-radiolabelled RV cellular binding and infectivity/replication. For the in situ study, a midline laparotomy was performed on 21-d-old formula-fed piglets and six 10 cm loops of ileum were isolated in situ. Briefly, 2 mg/ml of LNnT, aHMO mixture (40% 6'-SL/10 % 3'-SL/50 % SA) or media with or without the RV OSU strain (1 x 10(7) focus-forming units)were injected into the loops and maintained for 6 h. The loops treated with HMO treatments \u00fe RV had lower RV replication, as assessed by non-structural protein-4 (NSP4) mRNA expression, than RV-treated loops alone. In conclusion, SA-containing HMO inhibited RV infectivity in vitro; however, both neutral HMO and SA with aHMO decreased NSP4 replication during acute RV infection in situ."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Nutritional Sciences, University of Illinois, 338 Bevier Hall, 905 S. Goodwin Avenue, Urbana, IL 61801, USA."
          }
        ],
        "LastName": "Hester",
        "ForeName": "Shelly N",
        "Initials": "SN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Chen",
        "ForeName": "Xin",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Li",
        "ForeName": "Min",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Monaco",
        "ForeName": "Marcia H",
        "Initials": "MH"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Comstock",
        "ForeName": "Sarah S",
        "Initials": "SS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kuhlenschmidt",
        "ForeName": "Theresa B",
        "Initials": "TB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kuhlenschmidt",
        "ForeName": "Mark S",
        "Initials": "MS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Donovan",
        "ForeName": "Sharon M",
        "Initials": "SM"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 HD061929",
        "Acronym": "HD",
        "Agency": "NICHD NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "T32 DK59802",
        "Acronym": "DK",
        "Agency": "NIDDK NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Br J Nutr",
    "NlmUniqueID": "0372547",
    "ISSNLinking": "0007-1145"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "3'-sialyllactose"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "6'-sialyllactose"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Dietary Carbohydrates"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oligosaccharides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Messenger"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Viral Nonstructural Proteins"
    },
    {
      "RegistryNumber": "GZP2782OP0",
      "NameOfSubstance": "N-Acetylneuraminic Acid"
    },
    {
      "RegistryNumber": "J2B2A4N98G",
      "NameOfSubstance": "Lactose"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Acute Disease"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Diet"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Dietary Carbohydrates"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Models, Animal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Lactose"
    },
    {
      "QualifierName": [
        "chemistry"
      ],
      "DescriptorName": "Milk, Human"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "N-Acetylneuraminic Acid"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Oligosaccharides"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "RNA, Messenger"
    },
    {
      "QualifierName": [
        "classification",
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Rotavirus"
    },
    {
      "QualifierName": [
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "Rotavirus Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Species Specificity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Swine"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Viral Nonstructural Proteins"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Attachment"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Replication"
    }
  ]
}